Open AccessApatinib Inhibits Angiogenesis Via Suppressing Akt/GSK3β/ANG Signaling Pathway in Anaplastic Thyroid Cancer
Author(s) -
Zhijian Jin,
Xi Cheng,
Haoran Feng,
Jie Kuang,
Weiping Yang,
Chenghong Peng,
Baiyong Shen,
Weihua Qiu
Publication year - 2017
Publication title -
cellular physiology and biochemistry
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.486
H-Index - 87
eISSN - 1421-9778
pISSN - 1015-8987
DOI - 10.1159/000485583
Subject(s) - apatinib , angiogenesis , cancer research , protein kinase b , angiogenesis inhibitor , medicine , anaplastic thyroid cancer , cancer , apoptosis , thyroid cancer , chemistry , biochemistry
Anaplastic thyroid carcinoma (ATC) is one of the most lethal human malignancies, and there is no efficient method to slow its process. Apatinib, a novel tyrosine kinase inhibitor (TKI), has been confirmed for its efficacy and safety in the treatment of advanced gastric carcinoma patients. However, the effects of Apatinib in ATC are still unknown.